Clinical Trial Update: FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH) [Phase 3]

View source ↗

Summary

Phase 3 FREEDOM-C study evaluated oral treprostinil in combination with an endothelin receptor antagonist and/or a phosphodiesterase-5 inhibitor for pulmonary a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Orenitram (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2013-06-10